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Abstract
Background and objective: Chronic hypoxia induces pulmonary hypertension in mice. Smooth muscle cell 
hyperplasia and medial thickening characterize the vasculature of these animals. Thrombospondin-1 null (TSP-1-/-) 
mice spontaneously develop pulmonary smooth muscle cell hyperplasia and medial thickening. In addition, TSP-1 
produced by the pulmonary endothelium inhibits pulmonary artery smooth muscle cell growth. Based on these 
observations we sought to describe the pulmonary vascular changes in TSP-1-/- mice exposed to chronic hypoxia.
Methods: We exposed TSP-1-/- and wild type (WT) mice to a fraction of inspired oxygen (FiO2) of 0.1 for up to six 
weeks. Pulmonary vascular remodeling was evaluated using tissue morphometrics. Additionally, right ventricle systolic 
pressures (RVSP) and right ventricular hypertrophy by right ventricle/left ventricle + septum ratios (RV/LV+S) were 
measured to evaluate pulmonary hypertensive changes. Finally, acute pulmonary vasoconstriction response in both 
TSP-1-/- and WT mice was evaluated by acute hypoxia and U-46619 (a prostaglandin F2 analog) response.
Results: In hypoxia, TSP-1-/- mice had significantly lower RVSP, RV/LV+S ratios and less pulmonary vascular remodeling 
when compared to WT mice. TSP-1-/- mice also had significantly lower RVSP in response to acute pulmonary 
vasoconstriction challenges than their WT counterparts.
Conclusion: TSP-1-/- mice had diminished pulmonary vasoconstriction response and were less responsive to hypoxia-
induced pulmonary hypertension than their wild type counterparts. This observation suggests that TSP-1 could play an 
active role in the pathogenesis of pulmonary hypertension associated with hypoxia.
Background
Thrombospondin-1 (TSP-1) is expressed at high levels in
the heart, lungs, and liver of adult mice [1]. TSP-1 has
been reported to both stimulate and inhibit endothelial
cell and smooth muscle cell growth [2] smooth muscle
migration [3,4], and to both stimulate and inhibit angio-
genesis [5]. These contradictory findings are explained by
the ability of TSP-1 to interact with various matrix pro-
teins [6,7]. Consequently, TSP-1 has been implicated in
the pathogenesis and treatment of a variety of human dis-
eases including cancer [8], myocardial infarction [9] and
peripheral vascular disease [10].
In the lung, clinical evidence suggests that TSP-1 could
play a role in the pathogenesis of acute respiratory dis-
tress syndrome [11], idiopathic interstitial pneumonia
[12] and chronic obstructive pulmonary disease [13].
Currently, there are no clinical reports suggesting an
association between TSP-1 and pulmonary hypertension
(PH). Anatomic observations have shown that TSP-1 is
up-regulated in the lung vasculature of mice exposed to
chronic hypoxia [14] but its physiologic role in this set-
ting is currently not known.
TSP-1-/- mice developed pulmonary vascular smooth
muscle cell hyperplasia spontaneously [15]. In addition,
pulmonary artery endothelial cells undergoing cyclic
stretch produce proteins that inhibit pulmonary artery
smooth muscle cell growth and TSP-1 was responsible, at
least in part, for this growth inhibition [16].
In this context, the purpose of the present manuscript
was to describe the pulmonary vascular changes in TSP-
1-/-  mice exposed to chronic hypoxia since chronic
hypoxia induces pulmonary vascular remodeling and PH
in rats and mice. [17-29]. Here we show that in the
absence of the TSP-1 gene, mice were protected against
chronic hypoxia-induced PH when compared to controls.
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TSP-1-/- mice had lower right ventricular systolic pres-
sures (RVSP), right ventricle/left ventricle + septum
ratios (RV/LV+S), and less vascular remodeling than in
WT controls. TSP-1-/- mice also had decreased acute pul-
monary vasoconstriction in response to U-46619 and
acute hypoxia. Our data suggested that TSP-1 might play
an active role in the pathogenesis of PH associated with
hypoxic lung disease.
Methods
Animals
WT 129/SV male mice from Charles River Laboratories
(Wilmington, MA) weighting 20-25 g were placed in a
tightly sealed hypoxic chamber and provided with diet
and water ad libitum. 129/SV TSP-1-/- mice were a kind
gift from Dr. Jack Lawler and were bred and genotyped as
previously described [1]. TSP-1-/- mice have been found
to be susceptible to lung infection with D Streptoccocus
and Pasteurella pneumotropica [1]. To help prevent this
infection, a possible confounding factor in this research,
the animals were treated with Sulfamethoxazole and
Trimethoprim (200/40 mg - pediatric suspension-generic
brand -50383082416). The only animals that received
antibiotics were the TSP-1-/- mice. They only received
antibiotics while they were housed prior to hypoxia. Nei-
ther WT nor TSP-1-/- mice group received antibiotics
while they were exposed to hypoxia. A total of 93 animals
were studied with a minimum of 4 per group.
Hypoxic Chamber
The Subcommittee on Research Animal Care (SRAC) at
Massachusetts General Hospital approved the protocol
used in this study. The chronic hypoxia chamber is capa-
ble of housing 24 animals and has been described previ-
ously [30]. Oxygen concentrations were maintained at
FiO2 0.21 or at normobaric hypoxia FiO2 0.1 +/- 0.05 by
controlling the flow rates of compressed air and nitrogen.
Gases were circulated through the chamber by a fan. FiO2
of 0.1 produces an arterial PO2 of less than 60 mm Hg
[31]. Chamber oxygen concentration was tested daily by
mass spectrometry [17]. CO2 absorbent (barium hydrox-
i d e  l i m e ,  U S P;  W a r r e n  E.  C o l l i n s,  B r a i n t r e e ,  MA )  w a s
added to keep the CO2 content <0.4%. Husbandry was
done three times a week.
Measurements of right ventricular pressure
Before pressure measurements, at least one hour of
recovery was allowed following removal from hypoxia.
Animals (Wild type and TSP-1-/-) were removed from
hypoxia and anesthetized with Ketamine (90 mg/kg) and
Xylazine (10 mg/kg) intraperitoneally. Animals were
placed on a thermoregulated surgical plate and body tem-
perature was monitored and maintained at 37°C. Right
ventricular pressure was measured with the use of a sin-
gle lumen catheter (0.012" × 0.016" silicone tubing; Spe-
cialty Manufacturing Inc., Saginaw, MI) through the right
external jugular vein. Immediately after placement of the
catheter into the right ventricle, RVSP was measured with
a Gould pressure transducer positioned at the midthorax
of the animal and a Gould multichannel recorder (Gould
Inc., Cleveland, OH). Proper catheter location was veri-
fied by the waveform of the pressure tracing. The catheter
positioning was confirmed by necropsy. After obtaining
the right ventricular systolic pressure, animals were sacri-
ficed and used immediately for the determination of right
ventricular hypertrophy, hematocrit, and lung pathology.
Animals were euthanized by exsanguination. This
method is consistent with the Panel on Euthanasia of the
American Veterinary Medical Association.
Acute pulmonary vasoconstriction challenges
U-46619 (Cayman Chemical; Ann Arbor, MI) was diluted
following manufacturer's instructions. Animals were
anesthetized and catheterized through both external jug-
ular veins following the protocol described above. We
infused U-46619 at 0.1 ug/Kg [32] trough the left jugular
vein and measured the acute changes in RVSP thought
the right jugular vein. Percent increased in RVSP imme-
diately after U-46619 was calculated as RVSP post U-
46619 - baseline RVSP/RVSP post U-46619 × 100. To
carry out the acute hypoxic challenge, animals were anes-
thetized and right-heart catheterized followed by expo-
sure to FiO2 0.1 in a closed, custom-made Styrofoam
chamber. Changes in RVSP were measured 5, 10, and 15
minutes after the beginning of the exposure to hypoxia.
Acute FiO2 of 0.1 was achieved by using a commercial
available mix (Airgas; Hingham, MA) and acute oxygen
concentration was measured every 5 minutes using mass
spectrometry as described above.
Measurement of right ventricular hypertrophy
The degree of right ventricular hypertrophy was mea-
sured by the ratio of the weight of the right heart to left
hear heart. After removal of atria, the hearts were dis-
sected and then the right ventricle (RV) was separated
from the left ventricle and septum (LV+S) under a dis-
secting microscope (Braintree Scientific, Braintree, MA).
The dissected wet samples were weighed after drying at
90°C for 48 hr to obtain the ratio of RV/LV+S. We have
previously shown that drying the hearts for additional
days does not remove any additional water [17,30].
Evaluation of the pulmonary vasculature
The degree of pulmonary remodeling was assessed by
measuring the percent wall thickness of the vessels
(%WT) indexed to terminal bronchioles and intra-aci-
nous vessels (vessels indexed to respiratory bronchiole or
alveolar ducts) and the ratio of thick-walled vessels to
total number of intra-acinous vessels (% thick) as previ-Ochoa et al. Journal of Cardiothoracic Surgery 2010, 5:32
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ously described [17]. Briefly, the left lung of each animal
was perfusion-fixed with 10% natural formalin at a pres-
sure of 90 cm H2O for the pulmonary artery and 30 cm
H2O for the trachea and then preserved in fixative for at
least 48 hours. Paraffin-embedded lung tissues were sec-
tioned (4 μm thick) and stained with hematoxylin-eosin
and elastin staining (Verhoeff Van Gieson) for light
microscope examination. For the measurement of the
wall thickness of the vessels, a computer imaging analysis
software (IPLab; Scanlytics Inc., Fairfax, VA) was used to
capture images of individual pulmonary arteries with dig-
ital camera (Spot; Diagnostic Instruments Inc., Sterling
Heights, MI), mounted on a light microscope and linked
to a computer. To determine the percent thick-walled
vessel (%TW), external diameter (ED) and internal diam-
eter (ID) (defined as the distance between two diametri-
cally opposed external or internal elastic lamina) was
measured. The medial thickness of the vessel wall is
defined as distance between inner and outer elastic lam-
ina. The average of two measurements corresponding to
the largest and shortest ED and ID was determined.
%WT was calculated as (ED-ID)/ED × 100. Percent thick-
walled peripheral vessels (%TWPV) was expressed as the
number of thick-walled intra-acinous vessels divided by
the number of thick-plus thin-walled vessels × 100. Ves-
sels were considered thick-walled if they contained an
internal and external lamina for greater than 50% of the
circumference of the vessel.
Statistical Analysis
Statistical Analysis was performed using Statview 4.5
(Abacus Concepts, Inc and SAS Institute, Inc., Cary, NC).
The pulmonary hemodynamic measurements, hemat-
ocrit measurements, percent wall thickness, and percent
thick vessels after hypoxia were expressed as mean ±
standard error. Analysis of variance (ANOVA) was used
to assess the statistical significance of the differences fol-
lowed by Fisher's PLDS test for the values identified by
anova. We considered a p < 0.05 statistically significant.
Results
TSP-1-/- mice had lower Right Ventricular Systolic Pressures 
(RVSP) and Right Ventricle/Left Ventricle + Septum (RV/
LV+S) ratios than WT controls when exposed to 6 weeks of 
hypoxia
In normoxia, there was no difference in the RSVP
between TSP-1-/- mice and WT counterparts. However,
we found that TSP-1-/- mice failed to reach the same
RVSP and RV/LV+S ratios as WT mice did after 6 weeks
of hypoxia (Figures 1A and 1B). Hematocrits from WT
and TSP-1-/-  mice confirmed that both groups were
equally hypoxic throughout the experiment (Figure 1C)
and that hematocrits were not affected by the absence of
the TSP-1 gene.
TSP-1-/- mice developed less pulmonary vascular 
remodeling in response to chronic hypoxia than their WT 
controls
Pulmonary vascular remodeling, measured as %WT in
terminal bronchial arterioles and intra-acinous vessels,
Figure 1 TSP-1-/- mice have less pulmonary hypertension in re-
sponse to hypoxia. (A) Right ventricle systolic pressures (RVSP). (B) 
Right ventricle/left ventricle + septum ratios (RV/LV+S). (C) Hemat-
ocrits. * = p < 0.05 TSP-1+/+ black bar; TSP-1-/- gray bar.Ochoa et al. Journal of Cardiothoracic Surgery 2010, 5:32
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was significantly less in TSP-1-/- than in WT controls in
response to 6 weeks of hypoxia (Figure 2A and 2B). Like-
wise, percent thick-walled peripheral vessels (%TWPV)
remained unaffected in TSP-1-/-  mice (Figure 2C)
exposed to hypoxia.
TSP-1-/- mice had less acute pulmonary vasoconstriction in 
response to challenges than WT mice
To further explore the TSP-1-/- mice pulmonary vascula-
ture decreased reaction to chronic hypoxia we investi-
gated their response to acute pulmonary
vasoconstrictors. We used U-46619 and FiO2 0.1 (Figures
3A and 3B). TSP-1-/- mice showed a modest % increase in
RVSP (11.9% ± 3.05 Vs 41.3% ± 1.99 p < 0.05) in response
to U46619. TSP-1-/- mice had significantly lower rise in
RVSP after 15 minutes of acute hypoxia when compared
to their WT controls (41.8 mmHg ± 2.3 Vs 31 mmHg ±
0.6; p < 0.05)
Discussion
Although recent advances in the treatment of PH have
prolonged the survival of patients suffering from this dis-
ease, the basis for new and better therapeutics, as well as
a possible cure, are limited by our own capacity to com-
prehend the pathogenetic processes that control pulmo-
nary vascular remodeling and PH. This implies the need
for new observations, ideas, and fresh hypotheses that
might lead to new molecular targets for the treatment of
PH.
Thrombospondins are matricellular proteins composed
of multiple well-defined structural repeats. TSP-1 is both
antiangiogenic and proangiogenic. Through its central
type 1 repeat, TSP-1 is a potent antiangiogenic factor.
However, its N-terminal domain has pro-angiogenic
activity. These functional differences have been explained
on the ability of TSP-1 domains to interact with different
extracellular receptors.
Recent reports have shown that TSP-1 is up-regulated
by hypoxia in pulmonary arteries in piglets [33]. Likewise,
TSP-1 has been found in intrapulmonary arteries in
hypoxia-induced pulmonary hypertension in mice [14].
Nonetheless, the function of TSP-1 in the hypoxic pul-
monary vasculature is presently unknown.
Crawford et al. reported that TSP-1-/- mice had pulmo-
nary vascular smooth muscle cell hyperplasia and that
the abnormalities found in TSP-1-/- mice regressed once
the animals were treated with a TSP-1-derived peptide
[15]. Our own previous observations were in line with
these reports in that TSP-1 produced by the pulmonary
endothelium inhibited pulmonary smooth muscle growth
[16]. This suggested to us that the absence of TSP-1 could
result in increased pulmonary vascular remodeling in
animals exposed to chronic hypoxia. However, here we
show that TSP-1-/- mice were less responsive to the devel-
opment of PH when exposed to chronic hypoxia. TSP-1-/-
mice failed to reach the same right ventricle systolic pres-
sures (RVSP) and right ventricle/left ventricle +septum
ratios (RV/LV+S) as compared to WT controls at 6 weeks
Figure 2 TSP-1-/- mice have less pulmonary vascular remodeling 
in response to hypoxia. (A) Percent wall thickness of the vessels 
(%WT) indexed to terminal bronchioles vessels. (B) Percent wall thick-
ness of the vessels (%WT) indexed to intra-acinous vessels. (C) Ratio of 
thick-walled peripheral vessels to total number of intra-acinous vessels 
(% TWPV). * = p < 0.05.Ochoa et al. Journal of Cardiothoracic Surgery 2010, 5:32
http://www.cardiothoracicsurgery.org/content/5/1/32
Page 5 of 7
of hypoxia (Figure 1). In addition, TSP-1-/- mice devel-
o ped  l e s s  v a s c u l a r  r e m od e l i n g  t h a n  WT  c o n t r o l s  a f t e r
chronic hypoxia (Figure 2).
We further explored the lack of pulmonary vascular
remodeling and PH in TSP-1-/- mice by challenging them
with acute pulmonary vasoconstrictors (Figure 3). TSP-1-
/- mice had less acute pulmonary vasoconstriction than
WT controls in response to both acute hypoxia (FiO2 0.1)
and a thromboxane mimetic agent. This argued a possible
role of TSP-1 in acute smooth muscle cell tone and con-
traction. The lack of acute hypoxic response may have
contributed to the diminished pulmonary vascular
remodeling changes with chronic hypoxia.
Lawler et al. reported the first TSP-1-/- mouse [1]. They
showed that the absence of the TSP-1 gene was associ-
ated with the development of pneumonia. In our study,
we treated our animals with antibiotics prior to chronic
hypoxia in order to prevent any pulmonary infections.
Antibiotic treatment was stopped immediately before
hypoxia to prevent any effects of the medication on the
response to chronic hypoxia. Although, this did not pre-
vent completely the development of pneumonia, it
reduced the infection to a very small segmental area of
the right lung. Though this minimal airspace disease may
have contributed to a higher degree of hypoxemia, this
did not result in a larger rise in hematocrit as compared
to WT mice suggesting there was no significant differ-
ence in the degree of hypoxia (Figure 1). When we mea-
sured RVSP and vascular remodeling in normoxic TSP-1-
/- mice treated with antibiotics we were not able to con-
firm any pulmonary vascular remodeling compared to
the pulmonary vascular smooth muscle cell hyperplasia
reported in TSP-1-/- mice previously by Cra wford et al
[15] (Figure 2). This suggests that the pulmonary smooth
muscle cells hyperplasia found by Crawford et al. could
have been a simple response to the lung inflammation
caused by the lung infection. The pulmonary vascular
remodeling seemed to have ceded when antibiotics pre-
vented the pneumonia. The use of antibiotics might be
confounding variable in our study. However, the antibi-
otic we chose to use has a half-life of 24 minutes in mice
[34]. Second, the half-life and the length of our study
design (6 weeks) allowed us to make the assumption that
the animals cleared any residual antibiotic. Finally, there
is currently no evidence linking Sulfamethoxazole or
Trimethoprim with reduced smooth muscle cell contrac-
tility.
Even though we previously found that TSP-1 inhibited
pulmonary smooth muscle cell growth in vitro, the pres-
ent data shows that TSP-1 seems to stimulate pulmonary
smooth muscle cell growth in vivo. Although TSP-1 sup-
presses wound healing and granulation tissue formation
in the skin of transgenic mice [35]; antibody blockade to
TSP-1 reduces neointima formation in balloon-injured
rat carotid artery [36]. This suggests not only that TSP-1
functions are different in vitro and in vivo, but also that
its functions in vivo depend upon the physiological sys-
tem and cell type studied.
At this point we can only speculate on the role of TSP-1
in the pulmonary vasculature of chronic hypoxic mice.
Recently, TSP-1 has been recognized as a powerful inhib-
itor of the Nitric Oxide (NO)- cyclic GMP (cGMP) sig-
naling pathway in vascular cells [37,38]. The lack of
response in TSP-1-/- mice to hypoxia-induced pulmonary
hypertension could be explained on the basis of an NO/
cGMP "constitutively active" pathway due to the lack of
TSP-1 antagonism. This points to a pro-hypertensive role
Figure 3 TSP-1-/- mice have less acute pulmonary vasoconstric-
tion than WT controls. (A) Immediate percent increase of RVSP in re-
sponse to 0.1 ug/kg IV of U-46619. (B) Increase in RVSP after 5, 10, and 
15 minutes of acute hypoxia in WT (gray line) and TSP-1-/- mice (black 
line). * = p < 0.05 vs. WT. # p < 0.05 vs. WT at 15 minutes.Ochoa et al. Journal of Cardiothoracic Surgery 2010, 5:32
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for TSP-1 in vivo. Interestingly, Isenberg has proposed
that the high levels of circulating TSP-1 associated with
solid tumors could enhance tumor perfusion through
TSP-1's hypertensive activity [39]. The same group
reported that the systemic hypertensive response to epi-
nephrine is attenuated in TSP-1-/- mice [40]. Our obser-
vations suggest that TSP-1 function in sustaining vascular
tone in the systemic circulation could be reproduced in a
hypoxic model of pulmonary hypertension.
Conclusion
TSP-1-/- mice exposed to chronic hypoxia showed lower
RVSP, and RV/LV+S ratios as well as less pulmonary vas-
cular remodeling when compare to WT. These changes
can be explained by the lack of response of TSP-1-/- mice
to acute pulmonary vasoconstrictors. We interpret these
findings to mean that TSP-1 or TSP-1-dependent signal-
ing modules play an active role in regulating the vascular
reactivity of pulmonary vessels. TSP-1 or TSP-1-regu-
lated signaling cascades could be exploited as new molec-
ular targets in the treatment of pulmonary vascular
diseases.
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